Form S-8 ROCKET PHARMACEUTICALS,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
BTIG Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT), Defending on Weakness
December 22, 2022 1:51 PM ESTBTIG analyst Yun Zhong reiterated a Buy rating and $35.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "We believe the confirmation of a single-dose, open-label study, using natural history data as a comparator, as the pivotal study design should be a win for Rocket. The FDA's openness to considering a biomarker-based composite endpoint is encouraging, although a definitive agreement on an accelerated approval pathway relying on specific... More
Cowen Defending Rocket Pharmaceuticals (RCKT); 'shares should be up on this'
December 22, 2022 11:47 AM ESTCowen analyst Tyler Van Buren reiterated an Outperform rating on Rocket Pharmaceuticals (NASDAQ: RCKT)
The analyst comments "We caught up with mgmt after this morning's release, and they sound much better than the legal jargon ("openness"; "continued dialogue") in the release implies.... More
Evercore ISI Shines Some Light on Rocket Pharmaceuticals (RCKT) Regulatory Update
December 22, 2022 11:32 AM ESTEvercore ISI analyst Joshua Schimmer reiterated an Outperform rating and $75.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "I caught up with RCKT management after this mornings Danon gene therapy regulatory update. Seems like another December gift for an over-reaction to... More
